Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference

Rhea-AI Summary

Larimar Therapeutics (Nasdaq: LRMR), a clinical-stage biotechnology company, announced its participation in 1x1 investor meetings at the Guggenheim Virtual Neuro/Immunology Conference on November 15-16, 2021. The company focuses on developing treatments for complex rare diseases, with its lead compound CTI-1601 currently in a Phase 1 clinical program targeting Friedreich's ataxia. Larimar aims to utilize its intracellular delivery platform for other fusion proteins aimed at rare diseases characterized by deficiencies in intracellular bioactive compounds.

BALA CYNWYD, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1x1 investor meetings at the Guggenheim Virtual Neuro/Immunology Conference taking place November 15 – 16, 2021.

About Larimar Therapeutics

Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569

Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715

FAQ

What is the purpose of Larimar Therapeutics' participation in the Guggenheim Virtual Neuro/Immunology Conference?

Larimar Therapeutics is participating in 1x1 investor meetings at the conference to engage with potential investors and discuss its clinical programs.

What is CTI-1601 and what condition is it targeting?

CTI-1601 is Larimar Therapeutics' lead compound currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia.

When is the Guggenheim Virtual Neuro/Immunology Conference taking place?

The conference is scheduled for November 15-16, 2021.

What is the focus of Larimar Therapeutics as a biotechnology company?

Larimar Therapeutics focuses on developing treatments for complex rare diseases.

What platform does Larimar Therapeutics use for its drug development?

Larimar Therapeutics utilizes an intracellular delivery platform to design fusion proteins for targeting rare diseases.